UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 11, 2018

Streamline Health Solutions, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

0-28132 (Commission File Number)

31-1455414 (I.R.S. Employer Identification No.)

1230 Peachtree Street, NE, Suite 600 Atlanta, GA 30309

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (404) 446-2052

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

0

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02. Results of Operations and Financial Condition.

On September 11, 2018, Streamline Health Solutions, Inc. (the "Company") issued a press release announcing second quarter 2018 financial results. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Item 2.02, as well as Exhibit 99.1 referenced herein, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor incorporated by reference in any filing under the Securities Act of 1933, as amended, unless the Company expressly so incorporates such information by reference.

I	tem 9.01.	Financial	Statements	and	Exhibits.

(d) Exhibits.

99.1

EXHIBIT NUMBER DESCRIPTION

Press release, dated September 11, 2018, regarding Second Quarter 2018 Financial Results.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Streamline Health Solutions, Inc.

Date: September 11, 2018 By: <u>/s/ David Sides</u>

Name: David Sides

Title: President and Chief Executive Officer



News Release

STREAMLINE HEALTH® REPORTS SECOND QUARTER 2018 REVENUES OF \$5.3 MILLION; (\$1.5 MILLION) NET LOSS; ADJUSTED EBITDA OF \$0.4 MILLION

Total First Half Fiscal 2018 Revenue \$11.5 Million; Adjusted EBITDA \$1.0 Million

Atlanta, GA — **September 11, 2018** — Streamline Health Solutions, Inc. (NASDAQ: STRM), provider of integrated solutions, technology-enabled services and analytics supporting revenue cycle optimization for healthcare enterprises, today announced financial results for the second quarter and first half of fiscal 2018, which ended July 31, 2018.

Revenues for the three-month period ended July 31, 2018 decreased approximately 11% to \$5.3 million over the July 31, 2017 quarter revenue of \$5.9 million. Recurring revenue comprised 83% of total revenue in the quarter. Revenues for the first six months of fiscal year 2018 were \$11.5 million, down approximately 3% as compared to \$11.8 million in the first half of fiscal 2017.

Net loss for the second quarter was \$(1.5 million) as compared to a (\$1.1 million) net loss in the same period a year ago. Net loss for the first six months of fiscal 2018 was (\$2.1 million) as compared to (\$3.1 million) net loss for the same period in 2017.

Adjusted EBITDA for the second quarter 2018 was \$.4 million, down from \$.5 million in the second quarter of 2017. Adjusted EBITDA for the first six months of 2018 was \$1.0 million, as compared to \$45,000 in the first half of fiscal 2017.

"Our second quarter performance was particularly productive in many operational areas of our business. Our bookings included our first Abstracting client through our reseller agreement with Allscripts, and two new eValuator clients - one of which is a leading educational facility on the west coast, which uses Epic as their EMR provider," stated David Sides, President and Chief Executive Officer, Streamline Health. "We continue to find incremental efficiencies so that we can put these savings to work to fund future growth. In the second quarter we expanded the capabilities of eValuator from the original version of Inpatient rules-only to Outpatient; Profee — for physician practices; and Value-based Care (by adding HACs and PSIs). We believe we have a spectrum of advice for healthcare providers that no other competitor in the marketplace can match.

In addition, during the quarter we interviewed a number of qualified CFO candidates and feel very fortunate to have brought Tom Gibson on to our team at Streamline Health."

Highlights for the second quarter ended July 31, 2018 included:

- · Revenue for the second quarter 2018 was \$5.3 million;
- · Net loss for the second quarter 2018 was \$(1.5 million);
- · Adjusted EBITDA for the second quarter 2018 was \$0.4 million;
- · New sales bookings for the quarter were \$1.9 million; and
- · Backlog at the end of the quarter was \$23.4 million.

Conference Call Information

The Company will conduct a conference call to review the results on Wednesday, September 12, 2018 at 9:00 AM ET. Interested parties can access the call by joining the live webcast: <u>click here</u> to register. You can also join by phone by dialing 800-263-0877 and then entering passcode 1552127.

A replay of the conference call will be available from Wednesday, September 12, 2018 at 12:00 PM ET to Monday, September 17, 2018 at 12:00 PM ET by dialing 888-203-1112 and entering passcode 1552127.

*Non-GAAP Financial Measures

Streamline Health reports its financial results in accordance with U.S. generally accepted accounting principles ("GAAP"). Streamline Health's management also evaluates and makes operating decisions using various other measures. One such measure is adjusted EBITDA, which is a non-GAAP financial measure. Streamline Health's management believes that this measure provides useful supplemental information regarding the performance of Streamline Health's business operations.

Streamline Health defines "adjusted EBITDA" as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, and professional and advisory fees. A table reconciling this non-GAAP measure to net loss is included in this press release.

About Streamline Health

Streamline Health Solutions, Inc. (NASDAQ: STRM) is a healthcare industry leader in capturing, aggregating, and translating enterprise data into knowledge — producing actionable insights that support revenue cycle optimization for healthcare enterprises. We deliver integrated solutions and analytics that enable providers to drive reimbursement in a value-based world. We share a common calling and commitment to advance the quality of life and the quality of

healthcare — for society, our clients, the communities they serve, and the individual patient. For more information, please visit our website at www.streamlinehealth.net.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995

Statements made by Streamline Health Solutions, Inc. that are not historical facts are forward-looking statements that are subject to certain risks, uncertainties and important factors that could cause actual results to differ materially from those reflected in the forward-looking statements included herein. Forward-looking statements contained in this press release include, without limitation, statements regarding the Company's future growth, new sales bookings, backlog, results of investments in sales and marketing, competitive strengths, success of future products and related expectations and assumptions. These risks and uncertainties include, but are not limited to, the timing of contract

negotiations and execution of contracts and the related timing of the revenue recognition related thereto, the potential cancellation of existing contracts or clients not completing projects included in the backlog, the impact of competitive solutions and pricing, solution demand and market acceptance, new solution development and enhancement of current solutions, key strategic alliances with vendors and channel partners that resell the Company's solutions, the ability of the Company to control costs, availability of solutions from third party vendors, the healthcare regulatory environment, potential changes in legislation, regulation and government funding affecting the healthcare industry, healthcare information systems budgets, availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems, fluctuations in operating results, effects of critical accounting policies and judgments, changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other similar entities, changes in economic, business and market conditions impacting the healthcare industry generally and the markets in which the Company operates and nationally, and the Company's ability to maintain compliance with the terms of its credit facilities, and other risks detailed from time to time in the Streamline Health Solutions, Inc. filings with the U. S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The Company undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Company Contact:

Randy Salisbury SVP, Chief Marketing Officer (404) 229-4242 randy.salisbury@streamlinehealth.net

STREAMLINE HEALTH SOLUTIONS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

		Three Months Ended July 31,			Six Months Ended July 31,			
n.		2018		2017		2018		2017
Revenues:	ф	205.055	ф	220 602	ф	4 545 540	ф	E0E 44E
Systems sales	\$	385,875	\$	328,692	\$	1,517,549	\$	707,415
Professional services		271,121		571,812		509,435		991,847
Audit Services		247,843		294,441		607,556		639,460
Maintenance and support		3,216,251		3,278,562		6,525,355		6,633,334
Software as a service		1,147,642	_	1,442,652		2,372,010	_	2,867,784
Total revenues		5,268,732		5,916,159		11,531,905		11,839,840
Operating expenses:								
Cost of systems sales		289,890		596,799		539,874		1,162,850
Cost of professional services		697,467		543,206		1,403,697		1,258,421
Cost of audit services		300,081		391,439		694,060		832,078
Cost of maintenance and support		566,248		768,140		1,214,587		1,574,662
Cost of software as a service		281,872		285,832		598,259		625,208
Selling, general and administrative		2,518,893		2,790,171		5,767,950		6,163,699
Research and development		1,212,845		1,495,972		2,275,164		3,052,910
Loss on exit of operating lease		806,163		_		806,163		_
Total operating expenses		6,673,459		6,871,559		13,299,754		14,669,828
Operating loss		(1,404,727)		(955,400)		(1,767,849)		(2,829,988)
Other expense:								
Interest expense		(110,385)		(120,377)		(226,603)		(247,645)
Miscellaneous expense		(5,383)		(19,681)		(93,028)		(57,725)
Loss before income taxes		(1,520,495)		(1,095,458)		(2,087,480)		(3,135,358)
Income tax benefit		(1,713)		(2,607)		(3,427)		(5,215)
Net Loss	\$	(1,522,208)	\$	(1,098,065)	\$	(2,090,907)	\$	(3,140,573)
Net loss per common share — basic and diluted	\$	(0.08)	\$	(0.06)	\$	(0.10)	\$	(0.16)
Weighted average number of common shares — basic and	-		_		_			
diluted		19,971,090		19,834,859	_	19,978,757		19,765,125

STREAMLINE HEALTH SOLUTIONS, INC. CONSOLIDATED BALANCE SHEETS (Unaudited)

Assets

		July 31, 2018	 January 31, 2018
Current assets:			
Cash and cash equivalents	\$	3,246,395	\$ 4,619,834
Accounts receivable, net of allowance for doubtful accounts of \$267,221 and \$349,058, respectively		2,238,088	3,001,170
Contract receivables		826,277	223,791
Prepaid hardware and third-party software for future delivery		_	5,858
Prepaid client maintenance contracts		560,004	506,911
Other prepaid assets		828,257	742,232
Other current assets		367,326	546,885
Total current assets		8,066,347	9,646,681
	·		
Non-current assets:			
Property and equipment:			
Computer equipment		2,876,707	2,852,776
Computer software		704,562	730,950
Office furniture, fixtures and equipment		662,157	683,443
Leasehold improvements		582,271	729,348
		4,825,697	4,996,517
Accumulated depreciation and amortization		(3,956,221)	(3,834,153)
Property and equipment, net		869,476	1,162,364
Contract Receivables, less current portion		683,031	_
Capitalized software development costs, net of accumulated amortization of \$19,304,635 and \$18,658,183,			
respectively		5,190,076	4,307,351
Intangible assets, net		5,365,257	5,835,151
Goodwill		15,537,281	15,537,281
Other non-current assets		378,672	642,226
Total non-current assets		28,023,793	27,484,373
	\$	36,090,140	\$ 37,131,054

STREAMLINE HEALTH SOLUTIONS, INC. CONSOLIDATED BALANCE SHEETS (Unaudited)

Liabilities and Stockholders' Equity

	_	July 31, 2018		January 31, 2018
Current liabilities:	ф	700 000	ф	404 405
Accounts payable	\$	789,239	\$	421,425
Accrued compensation		883,386		342,351
Accrued other expenses		1,402,972		609,582
Current portion of long-term debt		596,984		596,984
Deferred revenues		8,273,251		9,481,807
Other		37,135		
Total current liabilities		11,982,967		11,452,149
Non-current liabilities:				
Term loan, net of deferred financing cost of \$92,808 and \$128,275, respectively		3,638,328		3,901,353
Royalty liability		874,437		2,469,193
Deferred revenues, less current portion		882,672		332,645
Other Liabilities		316,514		274,128
Total non-current liabilities		5,711,951		6,977,319
Total liabilities		17,694,918		18,429,468
Series A 0% Convertible Redeemable Preferred Stock, \$.01 par value per share, \$8,686,392 and \$8,849,985 redemption value, 4,000,000 shares authorized, 2,895,464 and 2,949,995 issued and outstanding, respectively		8,686,392		8,849,985
Stockholders' equity:				
Common stock, \$.01 par value per share, 45,000,000 shares authorized; 20,039,893 and 20,005,977 shares				
issued and outstanding, respectively		200,399		200,060
Additional paid in capital		82,284,445		81,776,606
Accumulated deficit		(72,776,024)		(72,125,065)
	_	(,,, ,	_	(,,)

STREAMLINE HEALTH SOLUTIONS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

	Six Months Ended,			
		July 31, 2018		July 31, 2017
Operating activities:				
Net loss	\$	(2,090,907)	\$	(3,140,573)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:				
Depreciation		324,640		403,090
Amortization of capitalized software development costs		646,452		1,143,624
Amortization of intangible assets		469,894		666,114
Amortization of other deferred costs		228,497		161,064
Valuation adjustment for warrants liability		_		(45,831)
Other valuation adjustments		56,211		86,192
Loss on exit of operating lease		806,163		_
Gain on disposal of fixed assets		(1,555)		(720)
Share-based compensation expense		366,906		555,229
Provision for accounts receivable		(64,154)		166,170
Changes in assets and liabilities, net of assets acquired:				
Accounts and contract receivables		292,442		99,068
Other assets		105,148		(333,401)
Accounts payable		367,814		449,929
Accrued expenses		587,226		(352,132)
Deferred revenues		(1,618,004)		(822,867)
Net cash provided by (used in) operating activities	_	476,773		(965,026)
Investing activities:				
Purchases of property and equipment		(14,457)		(9,812)
Proceeds from sales of property and equipment		14,225		
Capitalization of software development costs		(1,529,177)		(844,448)
Net cash used in investing activities		(1,529,409)		(854,260)
		(1,020, 100)	_	(65.,266)
Financing activities:				
Principal repayments on term loan		(298,492)		(813,197)
Principal payments on capital lease obligations		_		(68,149)
Payments related to settlement of employee shared-based awards		(57,699)		(37,002)
Proceeds from exercise of stock options and stock purchase plan		35,388		
Net cash used in financing activities		(320,803)		(918,348)
Net decrease in cash and cash equivalents		(1,373,439)		(2,737,634)
Cash and cash equivalents at beginning of year		4,619,834		5,654,093
Cash and cash equivalents at end of year	\$	3,246,395	\$	2,916,459
•	-	, , ,	<u> </u>	, ,

STREAMLINE HEALTH SOLUTIONS, INC.

Backlog (Unaudited) **Table A**

	July 31, 2018	January 31, 2018	July 31, 2017
Streamline Health Software Licenses	\$ 53,000	\$ 984, 000	\$ 11,458,000
Hardware and Third Party Software	_	_	50,000
Professional Services	1,867,000	2,048,000	3,517,000
Audit Services	1,019,000	1,293,000	1,454,000
Maintenance and Support	11,489,000	15,420,000	16,583,000
Software as a Service	8,936,000	13,048,000	13,300,000
Total	\$ 23,364,000	\$ 32,793,000	\$ 46,362,000

STREAMLINE HEALTH SOLUTIONS, INC.

New Bookings (Unaudited)

Table B

Three Months Ended July 31, 2018					
Value	% of				
	Total				

		Bookings
Streamline Health Software licenses	\$ 308,000	16%
Software as a service	756,000	40%
Maintenance and support	374,000	20%
Professional services	433,000	23%
Audit Services	33,000	2%
Total bookings	\$ 1,904,000	100%

Reconciliation of Non-GAAP Financial Measures (Unaudited) Table ${\bf C}$

This press release contains a non-GAAP financial measure under the rules of the U.S. Securities and Exchange Commission for Adjusted EBITDA. This non-GAAP information supplements and is not intended to represent a measure of performance in accordance with disclosures required by generally accepted accounting principles. Non-GAAP financial measures are used internally to manage the business, such as in establishing an annual operating budget. Streamline Health's management in its operating and financial decision-making uses non-GAAP financial measures because management believes these measures reflect ongoing business in a manner that allows meaningful period-to-period comparisons. Accordingly, the Company believes it is useful for investors and others to review both GAAP and non-GAAP measures in order to (a) understand and evaluate current operating performance and future prospects in the same manner as management does and (b) compare in a consistent

manner the Company's current financial results with past financial results. The primary limitations associated with the use of non-GAAP financial measures are that these measures may not be directly comparable to the amounts reported by other companies and they do not include all items of income and expense that affect operations. The Company's management compensates for these limitations by considering the Company's financial results and outlook as determined in accordance with GAAP and by providing a detailed reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures in the tables attached to this press release. Streamline Health defines "Adjusted EBITDA" as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, and professional and advisory fees.

Reconciliation of net earnings (loss) to non-GAAP Adjusted EBITDA (in thousands):

(Unaudited)

	Three Months Ended,			Six Months Ended,				
Adjusted EBITDA Reconciliation		July 31, 2018		July 31, 2017		July 31, 2018		July 31, 2017
Net loss	\$	(1,522)	\$	(1,098)	\$	(2,091)	\$	(3,141)
Interest expense		110		120		227		248
Income tax benefit		2		3		3		5
Depreciation		153		200		325		403
Amortization of capitalized software development costs		331		572		646		1,144
Amortization of intangible assets		235		333		470		666
Amortization of other costs		91		43		193		126
EBITDA		(600)		173		(227)		(549)
Share-based compensation expense		144		288		367		555
Gain on disposal of fixed assets		_		_		(2)		(1)
Non-cash valuation adjustments to assets and liabilities		5		23		56		40
Loss on exit of operating lease		806		_		806		_
Adjusted EBITDA	\$	355	\$	484	\$	1,000	\$	45
Adjusted EBITDA per diluted share	-							
Loss per share — diluted	\$	(80.0)	\$	(0.06)	\$	(0.10)	\$	(0.16)
Adjusted EBITDA per adjusted diluted share (1)	\$	0.02	\$	0.02	\$	0.04	\$	0.00
			=					
Diluted weighted average shares		19,971,090		19,834,859		19,978,757		19,765,125
Includable incremental shares — Adjusted EBITDA (2)		3,053,210		3,378,484		3,064,204		3,322,319
Adjusted diluted shares		23,024,300		23,213,343		23,042,961		23,087,444

⁽¹⁾ Adjusted EBITDA per adjusted diluted share for the Company's common stock is computed using the more dilutive of the two-class method or the ifconverted method.

⁽²⁾ The number of incremental shares that would be dilutive under profit assumption, only applicable under a GAAP net loss. If GAAP profit is earned in the current period, no additional incremental shares are assumed.